Position in EOLS
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$0
+$0 QoQ
Shares Held
0
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2024
4 quarters on record
Derivatives in EOLS
reported options exposure · as of Mar 31, 2026CallValue
$514,572
CallShares
125,200
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026DIADEMA PARTNERS LP holds $23,032,070 across 7 Drug Manufacturers - Specialty & Generic names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | UTHR |
UNITED THERAPEUTICS Corp
|
27,303 | $16,190,132 | |
| 2 | INDV |
Indivior Pharmaceuticals, Inc.
|
71,376 | $2,175,540 | |
| 3 | ALKS |
Alkermes plc.
|
50,000 | $1,768,000 | |
| 4 | BIOA |
BioAge Labs, Inc.
|
60,000 | $1,049,400 | |
| 5 | AYTU |
Aytu Biopharma, Inc
|
353,077 | $963,900 | |
| 6 | XERS |
Xeris Biopharma Holdings, Inc.
|
132,746 | $769,926 | |
| 7 | TLPH |
Talphera, Inc.
|
153,563 | $115,172 |
All Filings in EOLS
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $514,572 | 125,200 | Call | Sole | 2026-05-15 | |
| 2025-12-31 | $790,020 | 118,800 | Call | Sole | 2026-02-17 | |
| 2025-03-31 | $601,500 | 50,000 | Put | Sole | 2025-05-15 | |
| 2024-12-31 | $1,075,549 | 97,423 | Shares | Sole | 2025-02-14 | |
| No filing history on record for this holder in this stock. | ||||||